- Report
- July 2023
- 311 Pages
Global
From €3467EUR$3,600USD£2,982GBP
- Report
- September 2022
- 283 Pages
Global
From €7223EUR$7,500USD£6,212GBP
Obizur is a hematological drug used to treat bleeding episodes in adults with acquired hemophilia A. It is a recombinant human antithrombin (rhAT) that works by inhibiting the activity of clotting factors in the blood. Obizur is administered as an intravenous infusion and is indicated for the treatment of bleeding episodes in adults with acquired hemophilia A. Obizur is the only approved rhAT product for this indication.
Obizur is manufactured by Shire, a global biopharmaceutical company. Other companies in the Obizur market include CSL Behring, Grifols, and Octapharma. These companies are involved in the development and commercialization of hematological drugs, including Obizur. Show Less Read more